Bladder Cancer Advocacy Network
@BladderCancerUS
Followers
6K
Following
8K
Media
2K
Statuses
11K
Creating better todays and more tomorrows for bladder cancer patients and families since 2005.
Bethesda, MD
Joined January 2011
RT @PGrivasMDPhD: @fredhutch @uwurology team arrived in Houston! So fun to travel with brilliant colleague @spsutkaMD for @IBCG_BladderCA c….
0
3
0
RT @shilpaonc: @UroDocAsh kicking off the @IBCG_BladderCA 3rd annual mtg. Tremendous growth since 2006 now truly a global community of blad….
0
7
0
In @jclinicalinvest: Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer. Click here to read the article:
0
0
0
RT @PaulSargos: ✍️🇫🇷.SFRO: FRENCH GUIDELINES FOR THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF BLADDER CANCER.@SFjROfr. .
0
35
0
In PubMed: Top advances of 2024: Bladder cancer with @apolo_andrea @SaadAtiq24 @DrAndreKydd et. al. Click to read the article:
pubmed.ncbi.nlm.nih.gov
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-i...
0
4
9
In @JNanobiotech: Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes for enhancing the PDT of bladder cancer. Click here to read the article:
jnanobiotechnology.biomedcentral.com
Intravesical photodynamic therapy (PDT) emerges as a promising modality for bladder cancer treatment, yet its efficacy is often curtailed by weak muco-adhesion, poor muco-penetration, low tumor-tar...
0
1
3
In @OncNursingNews: Intravesical Mitomycin Produces 24-Month Response in Recurrent NMIBC. Click here to read the article:
oncnursingnews.com
New data showed a 72.2% DOR rate in patients with recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer who had a CR at 3 months.
0
1
4
In @Inside_PM: Bladder Cancer Resistance Mechanisms to Cisplatin Uncovered. Click here to read the article:
insideprecisionmedicine.com
The study identified cell signaling pathways that drive chemotherapy resistance, suggesting potential new methods for treating MIBC.
0
1
7
This morning, Good Morning America spotlighted TAR-200, @JNJNews's intravesical gemcitabine system for high-risk NMIBC. In trials, it achieved an 82.4% complete response rate, with over half cancer-free a year later. Watch:
0
1
5
RT @PGrivasMDPhD: Proud of our @fredhutch @uwurology team publishing this important study on CGA led by superstar @spsutkaMD . @urotoday @O….
0
10
0
RT @shilpaonc: And it's a wrap for #BCANTT25! Grateful for the opportunity to chair alongside my partner-in-crime @MaxKates this special 2….
0
5
0
When NIH budget cuts threatened cancer research, BCAN led a coalition of 40 cancer advocacy groups urging the Senate to protect vital federal investment in medical research. Read more:
0
1
4
In PubMed: Safety of Robot-Assisted Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Real-World Analysis Using the National Clinical Database in Japan. Click here to read the article:
pubmed.ncbi.nlm.nih.gov
RARC had a lower complication rate compared with ORC. LRC had comparable outcomes to RARC. The findings of this study contribute to RARC as being the standard treatment for MIBC.
0
0
0
Thank you for supporting #BCANTT25 and for being such a great partner, @engene_inc.
We were proud to sponsor and attend the @BladderCancerUS Think Tank during the organization’s 20th year of driving impact. Our team was honored to contribute to conversations that aim to improve quality of life for those impacted by bladder cancer.
0
0
2
RT @BrendanGuercio: See below for a crucial and very timely lifeline to preserve #bladdercancer research from @BladderCancerUS.
0
1
0
RT @bergsa83: 🚨‼️Another positive and practice changing trial for our patients! EV-303/KN-905 Cis-ineligible MIBC. Can’t wait to see the da….
0
9
0